152 related articles for article (PubMed ID: 15898611)
1. [Mesalazine is effective in Crohn disease].
Quartarolo JP
Ugeskr Laeger; 2005 Apr; 167(16):1767. PubMed ID: 15898611
[No Abstract] [Full Text] [Related]
2. [Mesalazine is effective in Crohn disease 2].
Quartarolo JP; Laegemidler F; Eskerod O
Ugeskr Laeger; 2005 Mar; 167(11):1308-9; author reply 1309. PubMed ID: 15830510
[No Abstract] [Full Text] [Related]
3. [Mesalazine is effective in Crohn disease 1].
Fallingborg J; Langholz E; Christensen LA; Munkholm P; Dahlerup JF
Ugeskr Laeger; 2005 Mar; 167(11):1307-8; author reply 1309. PubMed ID: 15830509
[No Abstract] [Full Text] [Related]
4. [Mesalazine is without clinical effect in patients with Crohn disease].
Munck LK
Ugeskr Laeger; 2005 Jan; 167(3):302-3. PubMed ID: 15704804
[No Abstract] [Full Text] [Related]
5. [Angioedema in Crohn's disease possibly due to mesalazine].
Nguyen-Khac E; Le Baron F; Thevenot T; Tiry-Lescut C; Tiry F
Gastroenterol Clin Biol; 2002 May; 26(5):535-6. PubMed ID: 12122371
[No Abstract] [Full Text] [Related]
6. [Mesalamine in the treatment of Crohn disease?].
Nielsen OH; Thomsen OO
Ugeskr Laeger; 2005 Apr; 167(15):1656-7. PubMed ID: 15892345
[No Abstract] [Full Text] [Related]
7. Mesalamine derivatives in the treatment of Crohn's disease.
Harrell LE; Hanauer SB
Gastroenterol Clin North Am; 2004 Jun; 33(2):303-17, ix-x. PubMed ID: 15177540
[TBL] [Abstract][Full Text] [Related]
8. Correction of mesalazine-induced neutropenia with high-dose G-CSF.
Bhidayasiri R; Katz JA; Sokos DR
Am J Gastroenterol; 2000 Nov; 95(11):3321-2. PubMed ID: 11095375
[No Abstract] [Full Text] [Related]
9. Mesalazine-induced aplastic anemia.
Wiesen A; Wiesen J; Limaye S; Kaushik N
Am J Gastroenterol; 2009 Apr; 104(4):1063. PubMed ID: 19259075
[No Abstract] [Full Text] [Related]
10. [Improved treatment of Crohn's disease].
Nau JY
Rev Med Suisse; 2005 May; 1(18):1241. PubMed ID: 15977716
[No Abstract] [Full Text] [Related]
11. Mesalazine-induced lupus.
Timsit MA; Anglicheau D; Lioté F; Marteau P; Dryll A
Rev Rhum Engl Ed; 1997 Oct; 64(10):586-8. PubMed ID: 9385697
[TBL] [Abstract][Full Text] [Related]
12. Presentation of Crohn's disease as metastatic cutaneous non-caseating granulomatous lesions.
Delgado J; Delgado B; Sztarkier I; Cagnano E; Sperber AD; Fich A
Isr Med Assoc J; 2003 Dec; 5(12):897-8. PubMed ID: 14689766
[No Abstract] [Full Text] [Related]
13. Aminosalicylates for active disease and in the maintenance of remission in Crohn's disease.
Feagan BG
Eur J Surg; 1998 Dec; 164(12):903-9. PubMed ID: 10029385
[No Abstract] [Full Text] [Related]
14. [Paradigmatic shift in drug treatment of Crohn disease].
Munck LK
Ugeskr Laeger; 2005 Aug; 167(33):3013. PubMed ID: 16109239
[No Abstract] [Full Text] [Related]
15. Mesalazine as a maintenance treatment in Crohn's disease.
Sutherland LR; Steinhart AH
Gut; 1998 Jan; 42(1):143-4. PubMed ID: 9505902
[No Abstract] [Full Text] [Related]
16. Mea culpa.
Hanauer SB
Nat Clin Pract Gastroenterol Hepatol; 2008 Aug; 5(8):409. PubMed ID: 18670441
[No Abstract] [Full Text] [Related]
17. The suspension of an announced trial on relapse prevention in Crohn's ileitis with a 5-ASA formulation in microgranular form.
Prantera C; Bellinvia S
Dig Liver Dis; 2005 Feb; 37(2):135-6. PubMed ID: 15733528
[No Abstract] [Full Text] [Related]
18. [Mesalazine for maintenance of medically-induced remission in Crohn disease: a survey of a Cochrane review].
Thomsen OØ; Nielsen OH
Ugeskr Laeger; 2005 Aug; 167(33):3015-7. PubMed ID: 16109240
[No Abstract] [Full Text] [Related]
19. Drug insight: aminosalicylates for the treatment of IBD.
Nielsen OH; Munck LK
Nat Clin Pract Gastroenterol Hepatol; 2007 Mar; 4(3):160-70. PubMed ID: 17339853
[TBL] [Abstract][Full Text] [Related]
20. Inflammatory pseudotumor of the liver as the first manifestation of Crohn's disease.
Amankonah TD; Strom CB; Vierling JM; Petrovic LM
Am J Gastroenterol; 2001 Aug; 96(8):2520-2. PubMed ID: 11513216
[No Abstract] [Full Text] [Related]
[Next] [New Search]
